Dynamic Capital Management Ltd bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, HoldingsChannel.com reports. The firm bought 10,635 shares of the medical equipment provider’s stock, valued at approximately $455,000.
A number of other large investors have also recently bought and sold shares of the stock. Creative Planning grew its stake in Hologic by 8.2% in the 4th quarter. Creative Planning now owns 15,396 shares of the medical equipment provider’s stock valued at $658,000 after buying an additional 1,161 shares during the last quarter. AT Bancorp grew its stake in Hologic by 2.2% in the 4th quarter. AT Bancorp now owns 62,329 shares of the medical equipment provider’s stock valued at $2,664,000 after buying an additional 1,323 shares during the last quarter. Norinchukin Bank The grew its stake in Hologic by 7.4% in the 3rd quarter. Norinchukin Bank The now owns 20,876 shares of the medical equipment provider’s stock valued at $766,000 after buying an additional 1,445 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in Hologic by 3.9% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 39,500 shares of the medical equipment provider’s stock valued at $1,449,000 after buying an additional 1,500 shares during the last quarter. Finally, Grove Bank & Trust grew its stake in Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 1,535 shares during the last quarter. Institutional investors and hedge funds own 96.95% of the company’s stock.
A number of research firms recently issued reports on HOLX. Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Friday, February 9th. Canaccord Genuity reiterated a “buy” rating and issued a $48.00 target price on shares of Hologic in a research note on Friday, February 9th. Deutsche Bank lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Friday, January 19th. Finally, Evercore ISI began coverage on shares of Hologic in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $48.00.
In related news, Director Namal Nawana purchased 6,600 shares of Hologic stock in a transaction on Tuesday, February 13th. The stock was purchased at an average cost of $37.88 per share, with a total value of $250,008.00. Following the acquisition, the director now directly owns 6,954 shares in the company, valued at $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 0.79% of the stock is owned by corporate insiders.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at $39.57 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. Hologic, Inc. has a 1-year low of $35.33 and a 1-year high of $46.80. The firm has a market cap of $10,940.00, a price-to-earnings ratio of 15.10, a price-to-earnings-growth ratio of 1.78 and a beta of 0.84.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The firm had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. During the same period in the prior year, the firm earned $0.52 EPS. The business’s revenue was up 7.7% on a year-over-year basis. equities research analysts predict that Hologic, Inc. will post 2.25 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/11/dynamic-capital-management-ltd-buys-shares-of-10635-hologic-inc-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.